Development of novel seeds for refractory peripheral neuropathy with iPS cell-derived megakaryocytes and platelets formulation.

2022 Fiscal Year Final Research Report

• Project/Area Number: 21K20961
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0906:Surgery related to the biological and sensory functions and related fields
• Research Institution: Chiba University
• Principal Investigator: Mukai Michiaki 千葉大学, 大学院医学研究院, 特任助教 (40907698)
• Project Period (FY): 2021-08-30 – 2023-03-31
• Keywords: iPS細胞 / 血小板 / 巨核球 / 神経障害 / 疼痛 / 多血小板血漿

Outline of Final Research Achievements

We established a decompression model for peripheral neuropathy that more closely resembles real clinical practice, in which decompression surgery (nerve dissection + strings removal) is performed a few days after creation of an existing chronic constriction model. We examined the cell dynamics in the nerve after decompression surgery and confirmed that T cell infiltration in injured nerve was suppressed by decompression surgery. Using this model, we also examined the effect of iPS cell-derived platelets/megakaryocytes (iPM) formulation on injured nerve recovery.

Free Research Field

再生医学

Academic Significance and Societal Importance of the Research Achievements

従来の末梢神経の疼痛に関する動物実験では、鑷子や糸による末梢神経絞扼モデルが採用されてきた。薬剤投与実験は、上記神経障害と同時に行われることが多く、神経障害による強い炎症と薬剤による神経保護効果が同時に起きるため、神経障害後の修復過程を評価することが困難であった。この問題に対し確立した神経除圧モデルは、今後の末梢神経の研究に寄与できると考える。
（iPM製剤の効果に関する内容については、後日再提出する。）